Substantial investment in rapid expansion to be the leading radiopharmacy network providing predictive and diagnostic molecular imaging products, services and related therapeutic products.
$2 Billion investment in the future of molecular imaging within the next 10 years.
$500M Investment in our existing radiopharmacy network to enhance our PET capability.
Doubling the size of our radiopharmacy network to 60 SPECT and PET pharmacies by 2023.
Investing in our product portfolio to bring your patients innovative diagnostic and therapeutic products.
Strengthening the supply chain through multi-sourcing to ensure patients are treated with unparalleled products when needed.
GE Channel Partner.

99.99991% - Confirmed accuracy rate for approximately three million doses dispensed annually (2)
>99% Product delivery record, regardless of weather conditions (rain, sleet, snow, or hail)
<1% Customer product complaint rate
Over 20 patient procedures per minute performed with RLS supplied products (4)
Full-service pharmacies located in key geographic areas.
*All services provided within a 100 mile radius of each pharmacy



